+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurological Biomarkers Market 2024-2028

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • TechNavio
  • ID: 5632924
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neurological biomarkers market is forecasted to grow by USD 7.82 bn during 2023-2028, accelerating at a CAGR of 13.01% during the forecast period. The report on the neurological biomarkers market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of neurological disorders, growth in clinical trials for neurological disease-specific biomarkers, and increasing initiatives and support from governments to improve neurological healthcare access.

The neurological biomarkers market is segmented as below:

By End-user

  • Hospitals
  • Clinical diagnostic centers
  • Research organizations and others

By Indication

  • AD
  • PD
  • ASD
  • MS
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increasing focus on accurate neurological diagnostics as one of the prime reasons driving the neurological biomarkers market growth during the next few years. Also, growing availability of blood-based biomarkers and evolution of manual miRNA will lead to sizable demand in the market.

The report on the neurological biomarkers market covers the following areas:

  • Neurological biomarkers market sizing
  • Neurological biomarkers market forecast
  • Neurological biomarkers market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurological biomarkers market vendors that include Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc.. Also, the neurological biomarkers market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global neurological biomarkers market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global neurological biomarkers market 2018 - 2022 ($ billion)
4.2 End-user Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - End-user Segment 2018 - 2022 ($ billion)
4.3 Indication Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Indication Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by End-user
6.1 Market segments
Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
6.2 Comparison by End-user
Exhibit 32: Chart on Comparison by End-user
Exhibit 33: Data Table on Comparison by End-user
6.3 Hospitals - Market size and forecast 2023-2028
Exhibit 34: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
6.4 Clinical diagnostic centers - Market size and forecast 2023-2028
Exhibit 38: Chart on Clinical diagnostic centers - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Clinical diagnostic centers - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Clinical diagnostic centers - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Clinical diagnostic centers - Year-over-year growth 2023-2028 (%)
6.5 Research organizations and others - Market size and forecast 2023-2028
Exhibit 42: Chart on Research organizations and others - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Research organizations and others - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Research organizations and others - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Research organizations and others - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by End-user
Exhibit 46: Market opportunity by End-user ($ billion)
Exhibit 47: Data Table on Market opportunity by End-user ($ billion)
7 Market Segmentation by Indication
7.1 Market segments
Exhibit 48: Chart on Indication - Market share 2023-2028 (%)
Exhibit 49: Data Table on Indication - Market share 2023-2028 (%)
7.2 Comparison by Indication
Exhibit 50: Chart on Comparison by Indication
Exhibit 51: Data Table on Comparison by Indication
7.3 AD - Market size and forecast 2023-2028
Exhibit 52: Chart on AD - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on AD - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on AD - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on AD - Year-over-year growth 2023-2028 (%)
7.4 PD - Market size and forecast 2023-2028
Exhibit 56: Chart on PD - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on PD - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on PD - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on PD - Year-over-year growth 2023-2028 (%)
7.5 ASD - Market size and forecast 2023-2028
Exhibit 60: Chart on ASD - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on ASD - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on ASD - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on ASD - Year-over-year growth 2023-2028 (%)
7.6 MS - Market size and forecast 2023-2028
Exhibit 64: Chart on MS - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on MS - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on MS - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on MS - Year-over-year growth 2023-2028 (%)
7.7 Others - Market size and forecast 2023-2028
Exhibit 68: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 70: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 71: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.8 Market opportunity by Indication
Exhibit 72: Market opportunity by Indication ($ billion)
Exhibit 73: Data Table on Market opportunity by Indication ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 77: Chart on Geographic comparison
Exhibit 78: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 107: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 France - Market size and forecast 2023-2028
Exhibit 111: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 112: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 113: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 114: Data Table on France - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 115: Market opportunity By Geographical Landscape ($ billion)
Exhibit 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 117: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 119: Overview on factors of disruption
11.4 Industry risks
Exhibit 120: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 121: Vendors covered
12.2 Market positioning of vendors
Exhibit 122: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 123: Abbott Laboratories - Overview
Exhibit 124: Abbott Laboratories - Business segments
Exhibit 125: Abbott Laboratories - Key news
Exhibit 126: Abbott Laboratories - Key offerings
Exhibit 127: Abbott Laboratories - Segment focus
12.4 ACROBIOSYSTEMS INC.
Exhibit 128: ACROBIOSYSTEMS INC. - Overview
Exhibit 129: ACROBIOSYSTEMS INC. - Product/Service
Exhibit 130: ACROBIOSYSTEMS INC. - Key offerings
12.5 Alseres Pharmaceuticals Inc
Exhibit 131: Alseres Pharmaceuticals Inc - Overview
Exhibit 132: Alseres Pharmaceuticals Inc - Product/Service
Exhibit 133: Alseres Pharmaceuticals Inc - Key offerings
12.6 Bio Rad Laboratories Inc.
Exhibit 134: Bio Rad Laboratories Inc. - Overview
Exhibit 135: Bio Rad Laboratories Inc. - Business segments
Exhibit 136: Bio Rad Laboratories Inc. - Key news
Exhibit 137: Bio Rad Laboratories Inc. - Key offerings
Exhibit 138: Bio Rad Laboratories Inc. - Segment focus
12.7 bioMerieux SA
Exhibit 139: bioMerieux SA - Overview
Exhibit 140: bioMerieux SA - Product/Service
Exhibit 141: bioMerieux SA - Key news
Exhibit 142: bioMerieux SA - Key offerings
12.8 Eli Lilly and Co.
Exhibit 143: Eli Lilly and Co. - Overview
Exhibit 144: Eli Lilly and Co. - Product/Service
Exhibit 145: Eli Lilly and Co. - Key news
Exhibit 146: Eli Lilly and Co. - Key offerings
12.9 F. Hoffmann La Roche Ltd.
Exhibit 147: F. Hoffmann La Roche Ltd. - Overview
Exhibit 148: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 149: F. Hoffmann La Roche Ltd. - Key news
Exhibit 150: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 151: F. Hoffmann La Roche Ltd. - Segment focus
12.10 IQVIA Holdings Inc.
Exhibit 152: IQVIA Holdings Inc. - Overview
Exhibit 153: IQVIA Holdings Inc. - Business segments
Exhibit 154: IQVIA Holdings Inc. - Key news
Exhibit 155: IQVIA Holdings Inc. - Key offerings
Exhibit 156: IQVIA Holdings Inc. - Segment focus
12.11 Merck KGaA
Exhibit 157: Merck KGaA - Overview
Exhibit 158: Merck KGaA - Business segments
Exhibit 159: Merck KGaA - Key news
Exhibit 160: Merck KGaA - Key offerings
Exhibit 161: Merck KGaA - Segment focus
12.12 Metabolon Inc.
Exhibit 162: Metabolon Inc. - Overview
Exhibit 163: Metabolon Inc. - Product/Service
Exhibit 164: Metabolon Inc. - Key offerings
12.13 PerkinElmer Inc
Exhibit 165: PerkinElmer Inc - Overview
Exhibit 166: PerkinElmer Inc - Business segments
Exhibit 167: PerkinElmer Inc - Key news
Exhibit 168: PerkinElmer Inc - Key offerings
Exhibit 169: PerkinElmer Inc - Segment focus
12.14 Proteome Sciences plc
Exhibit 170: Proteome Sciences plc - Overview
Exhibit 171: Proteome Sciences plc - Product/Service
Exhibit 172: Proteome Sciences plc - Key offerings
12.15 QIAGEN NV
Exhibit 173: QIAGEN NV - Overview
Exhibit 174: QIAGEN NV - Product/Service
Exhibit 175: QIAGEN NV - Key news
Exhibit 176: QIAGEN NV - Key offerings
12.16 Quanterix Corp.
Exhibit 177: Quanterix Corp. - Overview
Exhibit 178: Quanterix Corp. - Product/Service
Exhibit 179: Quanterix Corp. - Key offerings
12.17 Thermo Fisher Scientific Inc.
Exhibit 180: Thermo Fisher Scientific Inc. - Overview
Exhibit 181: Thermo Fisher Scientific Inc. - Business segments
Exhibit 182: Thermo Fisher Scientific Inc. - Key news
Exhibit 183: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 184: Thermo Fisher Scientific Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 185: Inclusions checklist
Exhibit 186: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 187: Currency conversion rates for US$
13.4 Research methodology
Exhibit 188: Research methodology
Exhibit 189: Validation techniques employed for market sizing
Exhibit 190: Information sources
13.5 List of abbreviations
Exhibit 191: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by End-user
Exhibits 6: Executive Summary - Chart on Market Segmentation by Indication
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global neurological biomarkers market 2018 - 2022 ($ billion)
Exhibits 19: Historic Market Size - End-user Segment 2018 - 2022 ($ billion)
Exhibits 20: Historic Market Size - Indication Segment 2018 - 2022 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on End-user - Market share 2023-2028 (%)
Exhibits 31: Data Table on End-user - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by End-user
Exhibits 33: Data Table on Comparison by End-user
Exhibits 34: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
Exhibits 35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
Exhibits 36: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Clinical diagnostic centers - Market size and forecast 2023-2028 ($ billion)
Exhibits 39: Data Table on Clinical diagnostic centers - Market size and forecast 2023-2028 ($ billion)
Exhibits 40: Chart on Clinical diagnostic centers - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Clinical diagnostic centers - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Research organizations and others - Market size and forecast 2023-2028 ($ billion)
Exhibits 43: Data Table on Research organizations and others - Market size and forecast 2023-2028 ($ billion)
Exhibits 44: Chart on Research organizations and others - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Research organizations and others - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by End-user ($ billion)
Exhibits 47: Data Table on Market opportunity by End-user ($ billion)
Exhibits 48: Chart on Indication - Market share 2023-2028 (%)
Exhibits 49: Data Table on Indication - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Indication
Exhibits 51: Data Table on Comparison by Indication
Exhibits 52: Chart on AD - Market size and forecast 2023-2028 ($ billion)
Exhibits 53: Data Table on AD - Market size and forecast 2023-2028 ($ billion)
Exhibits 54: Chart on AD - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on AD - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on PD - Market size and forecast 2023-2028 ($ billion)
Exhibits 57: Data Table on PD - Market size and forecast 2023-2028 ($ billion)
Exhibits 58: Chart on PD - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on PD - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on ASD - Market size and forecast 2023-2028 ($ billion)
Exhibits 61: Data Table on ASD - Market size and forecast 2023-2028 ($ billion)
Exhibits 62: Chart on ASD - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on ASD - Year-over-year growth 2023-2028 (%)
Exhibits 64: Chart on MS - Market size and forecast 2023-2028 ($ billion)
Exhibits 65: Data Table on MS - Market size and forecast 2023-2028 ($ billion)
Exhibits 66: Chart on MS - Year-over-year growth 2023-2028 (%)
Exhibits 67: Data Table on MS - Year-over-year growth 2023-2028 (%)
Exhibits 68: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 69: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 70: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 71: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 72: Market opportunity by Indication ($ billion)
Exhibits 73: Data Table on Market opportunity by Indication ($ billion)
Exhibits 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 77: Chart on Geographic comparison
Exhibits 78: Data Table on Geographic comparison
Exhibits 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 107: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 108: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 109: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 110: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 111: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibits 112: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibits 113: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits 114: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits 115: Market opportunity By Geographical Landscape ($ billion)
Exhibits 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits 117: Impact of drivers and challenges in 2023 and 2028
Exhibits 118: Overview on Criticality of inputs and Factors of differentiation
Exhibits 119: Overview on factors of disruption
Exhibits 120: Impact of key risks on business
Exhibits 121: Vendors covered
Exhibits 122: Matrix on vendor position and classification
Exhibits 123: Abbott Laboratories - Overview
Exhibits 124: Abbott Laboratories - Business segments
Exhibits 125: Abbott Laboratories - Key news
Exhibits 126: Abbott Laboratories - Key offerings
Exhibits 127: Abbott Laboratories - Segment focus
Exhibits 128: ACROBIOSYSTEMS INC. - Overview
Exhibits 129: ACROBIOSYSTEMS INC. - Product/Service
Exhibits 130: ACROBIOSYSTEMS INC. - Key offerings
Exhibits 131: Alseres Pharmaceuticals Inc - Overview
Exhibits 132: Alseres Pharmaceuticals Inc - Product/Service
Exhibits 133: Alseres Pharmaceuticals Inc - Key offerings
Exhibits 134: Bio Rad Laboratories Inc. - Overview
Exhibits 135: Bio Rad Laboratories Inc. - Business segments
Exhibits 136: Bio Rad Laboratories Inc. - Key news
Exhibits 137: Bio Rad Laboratories Inc. - Key offerings
Exhibits 138: Bio Rad Laboratories Inc. - Segment focus
Exhibits 139: bioMerieux SA - Overview
Exhibits 140: bioMerieux SA - Product/Service
Exhibits 141: bioMerieux SA - Key news
Exhibits 142: bioMerieux SA - Key offerings
Exhibits 143: Eli Lilly and Co. - Overview
Exhibits 144: Eli Lilly and Co. - Product/Service
Exhibits 145: Eli Lilly and Co. - Key news
Exhibits 146: Eli Lilly and Co. - Key offerings
Exhibits 147: F. Hoffmann La Roche Ltd. - Overview
Exhibits 148: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 149: F. Hoffmann La Roche Ltd. - Key news
Exhibits 150: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 151: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 152: IQVIA Holdings Inc. - Overview
Exhibits 153: IQVIA Holdings Inc. - Business segments
Exhibits 154: IQVIA Holdings Inc. - Key news
Exhibits 155: IQVIA Holdings Inc. - Key offerings
Exhibits 156: IQVIA Holdings Inc. - Segment focus
Exhibits 157: Merck KGaA - Overview
Exhibits 158: Merck KGaA - Business segments
Exhibits 159: Merck KGaA - Key news
Exhibits 160: Merck KGaA - Key offerings
Exhibits 161: Merck KGaA - Segment focus
Exhibits 162: Metabolon Inc. - Overview
Exhibits 163: Metabolon Inc. - Product/Service
Exhibits 164: Metabolon Inc. - Key offerings
Exhibits 165: PerkinElmer Inc - Overview
Exhibits 166: PerkinElmer Inc - Business segments
Exhibits 167: PerkinElmer Inc - Key news
Exhibits 168: PerkinElmer Inc - Key offerings
Exhibits 169: PerkinElmer Inc - Segment focus
Exhibits 170: Proteome Sciences plc - Overview
Exhibits 171: Proteome Sciences plc - Product/Service
Exhibits 172: Proteome Sciences plc - Key offerings
Exhibits 173: QIAGEN NV - Overview
Exhibits 174: QIAGEN NV - Product/Service
Exhibits 175: QIAGEN NV - Key news
Exhibits 176: QIAGEN NV - Key offerings
Exhibits 177: Quanterix Corp. - Overview
Exhibits 178: Quanterix Corp. - Product/Service
Exhibits 179: Quanterix Corp. - Key offerings
Exhibits 180: Thermo Fisher Scientific Inc. - Overview
Exhibits 181: Thermo Fisher Scientific Inc. - Business segments
Exhibits 182: Thermo Fisher Scientific Inc. - Key news
Exhibits 183: Thermo Fisher Scientific Inc. - Key offerings
Exhibits 184: Thermo Fisher Scientific Inc. - Segment focus
Exhibits 185: Inclusions checklist
Exhibits 186: Exclusions checklist
Exhibits 187: Currency conversion rates for US$
Exhibits 188: Research methodology
Exhibits 189: Validation techniques employed for market sizing
Exhibits 190: Information sources
Exhibits 191: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global neurological biomarkers market: Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing focus on accurate neurological diagnostics.'

According to the report, one of the major drivers for this market is the rising incidence of neurological disorders.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • ACROBIOSYSTEMS INC.
  • Advanced Brain Monitoring Inc.
  • Alseres Pharmaceuticals Inc
  • Bio Rad Laboratories Inc.
  • bioMerieux SA
  • Charles River Laboratories International Inc.
  • EATRIS ERIC
  • Eli Lilly and Co.
  • Enzo Biochem Inc.
  • F. Hoffmann La Roche Ltd.
  • Fujirebio Holdings Inc.
  • IQVIA Holdings Inc.
  • Merck KGaA
  • Metabolon Inc.
  • PerkinElmer Inc
  • Proteome Sciences plc
  • QIAGEN NV
  • Quanterix Corp.
  • Thermo Fisher Scientific Inc.